Alamar Biosciences, Inc. is a commercial-stage proteomics company engaged in protein detection and analysis. The Company's proprietary NULISA (Nucleic Acid Linked Immuno-Sandwich Assay) technology addresses the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, dynamic range and automation. Its integrated platform consists of proprietary instruments, consumables and analytical software that is designed to provide scientists with an end-to-end solution to precisely and consistently measure from one to hundreds of low-abundances and difficult-to-detect biomarkers across the continuum of discovery, translational research and ultimately diagnostics. Its instrument, the ARGO HT System, is designed to fully automate high-sensitivity and high-plex proteomics analysis and is available for research use only applications.
äŒæ¥ã³ãŒãALMR
äŒç€ŸåAlamar Biosciences Inc
äžå Žæ¥Apr 17, 2026
æé«çµå¶è²¬ä»»è
ãCEOãLuo (Yuling)
åŸæ¥å¡æ°- -
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«- -
æ¬ç€Ÿæåšå°47071 Bayside Pkwy
éœåžFREMONT
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·94538
é»è©±çªå·15106269888
ãŠã§ããµã€ãhttps://alamarbio.com
äŒæ¥ã³ãŒãALMR
äžå Žæ¥Apr 17, 2026
æé«çµå¶è²¬ä»»è
ãCEOãLuo (Yuling)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã